Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: Outcomes in the Japanese subgroup of the VIEW 2 study
Background/aims To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial. Methods In this double-masked study, patients were randomised to: 0.5 mg IVT-AFL every 4 weeks (0.5q4); 2 mg IVT-AFL ever...
Main Authors: | Ogura, Y, Terasaki, H, Gomi, F, Yuzawa, M, Iida, T, Honda, M, Nishijo, K, Sowade, O, Komori, T, Schmidt-Erfurth, U, Simader, C, Chong, V |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BMJ Publishing Group
2014
|
Similar Items
-
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: Outcomes in the Japanese subgroup of the VIEW 2 study
by: Ogura, Y, et al.
Published: (2014) -
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
by: Heier, J, et al.
Published: (2012) -
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration
by: Heier, J, et al.
Published: (2012) -
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
by: Schmidt-Erfurth, U, et al.
Published: (2014) -
Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies
by: Schmidt-Erfurth, U, et al.
Published: (2014)